drugbank id	name	groups	pubchem id	description	indication	target(s)	score
DB03014	Heme	experimental	4973			P09601;P0A387;Q8GGK7;Q939D2;P35354;Q9L142;P68871;P95522;Q9Z4P4;Q9Z4P0;P82291;P35520;Q8RBX6;P0C278;P02144;P81154;P82599;Q9RGD9;P00150;Q54450;P81238;Q00441;Q52369;P00167;Q9UJM8;P21179;P04164;P04040;Q74BP5;P00083;P00080;P11712;P72849;P04252;O31607;P33260;Q15735;Q9XCU0;O07621;P72181;P00099;P00094;P00091;P00132;P00133;Q9KZR7;P00131;P20813;P73925;P10955;P76129;P72322;P09917;P51687;Q9RN68;Q9L915;Q834P5;P00147;P29474;P29475;P00149;Q57142;P83787;O43169;Q8E9W8;Q8VNU2;P0A514;P42321;P0A512;Q9HX49;O34453;Q9KIZ4;P22759;P24232;P23222;Q8GR64;P83223;O31440;Q8VQF6;P69891;P00118;P71119;P02790;P08684;P24092;P23219;P35228;P0A595;P0A592;Q9S1E5;Q50925;Q5SME3;P74133;Q746J6;Q9NPG2;Q31MN3;O69002;Q59738;P10632;Q8RN04;Q9FCA6;P99999;P0ABE7;Q8EDL6;P94690;P14774;P14779;Q08129;Q8WWM9;P82603;P29422;Q9F3S9;P55929;P46206;P00183;Q8RN03;P0A094;P77872;P39662;P44654	0.983909097086
DB02235	Methionine Sulfoxide	experimental	9577091			P05067;P29422;Q93UV9	0.93795
DB07001	(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine	experimental	24941263			P29474	0.933116
DB02994	Hydroxydimethylarsine Oxide	experimental	2513			P11488;P12497;P29474;P15121	0.933116
DB03918	6s-5,6,7,8-Tetrahydrobiopterin	experimental	5702551			P29474	0.933116
DB03332	5,6-Cyclic-Tetrahydropteridine	experimental	6323220			P29474	0.933116
DB01686	N,N-dimethylarginine	experimental	123831	Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. [Wikipedia]		P29474;P35228	0.933116
DB07244	5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE	experimental	6914633			P00797;P29474	0.933116
DB02207	7-Nitroindazole	experimental	1893			P35228;P29474	0.933116
DB03144	N-Omega-Hydroxy-L-Arginine	experimental	123895			O34453;P05089;P35228;P29474;P29475	0.933116
DB03974	L-Homoarginine	experimental	5288582			P29474	0.933116
DB00155	L-Citrulline	approved;nutraceutical	9750	Citrulline is an amino acid.  It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a by-product of the reaction catalyzed by NOS family.  Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.	Used for nutritional supplementation, also for treating dietary shortage or imbalance.	Q9Y2J8;O94760;P00480;P00966;Q9UM07;O95865;Q6TGC4;Q5T6L4;Q9ULW8;P29474;P29475;Q9ULC6;P35228	0.933116
DB03963	S-(Dimethylarsenic)Cysteine	experimental	46936846			Q9Y678;Q13426;P0A745;P16753;P12497;P29474;O60603;P03300	0.933116
DB01110	Miconazole	approved	4189	An imidazole antifungal agent that is used topically and by intravenous infusion. [PubChem]	For topical application in the treatment of tinea pedis (athlete&rsquo;s foot), tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, and <i>Epidermophyton floccosum</i>, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.	P10613;Q12809;Q9Y691;Q9NS40;O15554;Q16558;Q92952;Q9NPA1;Q9H2S1;P29474;Q86W47;Q9UGI6;Q9H252;P35228;Q12791	0.933116
DB01821	L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide	experimental	46936229			P29474;P29475	0.933116
DB02692	(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin	experimental	5702551			P00439;P35228;P29474;P29475	0.933116
DB08019	N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine	experimental	25021186			P29474;P29475	0.933116
DB03100	6-Nitroindazole	experimental	24239			P29474;P35228	0.933116
DB08018	N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE	experimental	24798097			P29474;P29475	0.933116
DB03305	N5-Iminoethyl-L-Ornithine	experimental	40489058			P29474	0.933116
DB02335	2-Aminothiazoline	experimental	15689			P29474	0.933116
DB02589	Se-Ethyl-Isoselenourea	experimental	449633			P29474	0.933116
DB00360	Tetrahydrobiopterin	approved	1125	Tetrahydrobiopterin or BH4 is a cofactor in the synthesis of nitric oxide. It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of tryptophan to 5-hydroxytryptophan via tryptophan hydroxylase. [Wikipedia]	For the treatment of tetrahydrobiopterin (BH4) deficiency.	P17752;P00439;P07101;P29474	0.933116
DB02077	L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide	experimental	656912			P29474;P29475	0.933116
DB01833	L-2-Amino-4-(Guanidinooxy)Butyric Acid	experimental	439202			P29474	0.933116
DB03065	7-Nitroindazole-2-Carboxamidine	experimental	1894			P29474	0.933116
DB07388	ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE	experimental	11149707			P29474;P35228	0.933116
DB04018	S-Isopropyl-Isothiourea	experimental	445319			P29474	0.933116
DB02234	Ethylisothiourea	experimental	5139			P0A094;P29474;P35228	0.933116
DB04223	Nitroarginine	experimental	440005	An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6)		P29474;P29475	0.933116
DB02027	N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine	experimental	656911			P29474;P29475	0.933116
DB04559	N-(Chlorophenyl)-N'-Hydroxyguanidine	experimental	181426			P29474	0.933116
DB02141	S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea	experimental	1337			P29474	0.933116
DB02911	2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine	experimental	445109			P29474	0.933116
DB02044	N-(3-(Aminomethyl)Benzyl)Acetamidine	experimental	1433			P35228;P29474;P29475	0.933116
DB04534	5-Nitroindazole	experimental	21501			P29474;P35228	0.933116
DB00125	L-Arginine	approved;nutraceutical	6322	An essential amino acid that is physiologically active in the L-form. [PubChem]	Used for nutritional supplementation, also for treating dietary shortage or imbalance.	Q96A70;P04424;Q8WY07;P78540;P30825;O43246;P29474;P00966;P35228	0.933116
DB01997	3-Bromo-7-Nitroindazole	experimental	1649			P35228;P29474;P29475	0.933116
DB03707	S-Ethyl-N-Phenyl-Isothiourea	experimental	347590			P29474;P29475	0.933116
DB03910	S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea	experimental	1331			P29474	0.933116
DB02979	N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane	experimental	11740154			P29474	0.933116
DB02048	1,2,4-Triazole-Carboxamidine	experimental	3387240			P29474	0.933116
DB08888	Ocriplasmin 	approved		Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains.  Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012. 	Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion. 	P08697;P01023;P02751	0.929444
DB00102	Becaplermin	approved		Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds	For topical treatment of skin ulcers (from diabetes)	P01023;P09619;P16234	0.929444
DB00626	Bacitracin	approved		Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically.

Bacitracin is synthesised via the so-called nonribosomal peptide synthetases (NRPSs), which means that ribosomes are not involved in its synthesis.	For the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. Also used in ointment form for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound infections. Used against gram positive bacteria. Bacitracin is also used as an inhibitor of proteases and other enzymes. 
However, specific activity of bactracin's inhibition of protein disulfide isomerase has been called into question. 	P01023;P14735	0.929444
DB02944	Alpha-D-Mannose	experimental	6992084	A hexose or fermentable monosaccharide and isomer of glucose from manna, the ash Fraxinus ornus and related plants. (From Grant & Hackh&#39;s Chemical Dictionary, 5th ed & Random House Unabridged Dictionary, 2d ed)		P04054;P06820;P49424;P03315;P10144;P08100;P01130;Q9Y286;P11717;P36913;P24855;P32927;P30328;P52799;P05546;Q9NNX6;Q9BZR6;P09848;P25311;Q59288;P27915;P08069;P01854;P03391;P06276;P16410;Q9UKM7;P36222;P11226;Q10472;P07339;Q9HYN5;P29460;P02671;P03437;P01008;P15309;P77847;P01574;P12528;Q9UKY3;P81180;P08236;P01215;P35936;Q46079;P12319;P42658;P31723;P05884;P07359;P80188;P06729;P03472;P15529;P17342;P23219;P13688;P33908;P00736;P01859;P09382;Q9BZ11;P08887;P61626;P23141;P01857;P19961;P02788;P06280;P12564;P29475;Q9ZF13;P02749;P27487;O75976	0.925694003343
DB00064	Serum albumin iodonated	approved		A diagnostic radiopharmaceutical containing iodinated I 131 albumin for intravenous imaging. Following intravenous injection, radioiodinated albumin human is uniformly distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly (2 days). Indicated for use in determinations of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times	For determination of total blood and plasma volumes	P02760;P02735;P02649	0.909652
DB00062	Human Serum Albumin	approved		Human serum albumin isolated from expired blood plasma	For treatment of severe blood loss, hypervolemia, hypoproteinemia	P02760;P02735;P02649	0.909652
DB07585	5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	experimental	24798742			P49841;P31749	0.903772
DB03431	Adenosine-5'-Diphosphate	experimental	5702665	Adenosine 5&#39;-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5&#39;-position. [PubChem]		P08107;P22259;P54278;P0A4Z2;P74881;Q9CHL8;P43773;P04425;Q7BK04;Q9BW19;P10153;P07900;O34797;P06710;Q03518;Q9BZX2;P27707;Q16774;Q05397;P23919;P0A6I3;Q72H90;P0A6I9;P06855;Q5SH23;P00497;P40937;Q48745;O14727;P49137;O15066;P61221;P0A6W9;Q13838;Q9WXM9;P35749;P00367;O94832;P24425;P03070;P15879;P23677;P03176;O00764;P00558;P55072;P51570;P07998;Q04230;Q9WZW1;P13000;O66659;P0A1P6;P33176;P0A5Y8;Q9HTN2;P14625;P48637;P14900;P0ABH9;P62219;O14983;P26281;Q56313;Q56310;P0A3F3;P28366;P83820;P0A6F3;P0A820;P11904;P78362;O14874;P04035;P75430;P33221;P49368;P0A7G9;P68133;Q59560;P13569;P69441;O14965;P30085;P08238;Q83MF7;P10721;Q15119;P10880;P0A3Y5;Q97F65;Q746L7;P15531;O43252;Q7Z406;Q99661;P06732;P19367;P03132;P09029;P08690;P11568;Q8N139;P52732;O67198;P00459;P0A6Z3;Q96QT4;Q00266;Q94M05;P11142;P16099;P0A9J6;P0A6C8;P08192;O25926;Q12756;P44492;P49841;Q969G6;Q9LCZ4	0.903772
DB08073	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	experimental	10172943			P17612;P49841;P61925;P31751	0.903772
DB04014	Alsterpaullone	experimental	5005498			Q00535;P49841;P06493;O75100	0.903772
DB03444	(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime	experimental	5287844			P49841	0.903772
DB02010	Staurosporine	experimental	44120114	An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)		Q04759;P11309;O15530;P48736;P41240;P24941;P43405;P49841;P06239;P43403;P49137;Q08881	0.903772
DB01950	N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea	experimental	448014			P49841	0.903772
DB04395	Phosphoaminophosphonic Acid-Adenylate Ester	experimental	44462678	5&#39;-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [PubChem]		P37093;Q83LD8;P08069;Q6L8F0;P78362;Q06609;P19367;Q9WZ57;P23677;Q16877;P33221;P29317;P11309;P23837;P23367;P49368;P0A6C8;P0A7G9;P68133;P55072;P03960;P23919;P45510;P51570;P13569;P0AEJ4;Q02880;P68400;Q99661;Q9RA63;Q96QT4;Q04230;P53778;P06239;P0A6I3;P08690;P48637;P45066;P49841;P59846;P20083;P0A3Y5;P0AES6;Q12756;P29323;Q56310;P53355;P0A6H7;Q9LCZ4;P53779;P0A820	0.903772
DB01793	I-5	experimental	448008			P49841	0.903772
DB07058	5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione	experimental	25181321			P49841	0.903772
DB07584	N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	experimental	24798741			P49841;P31749	0.903772
DB02052	Indirubin-3'-Monoxime	experimental	5326739			P06493;O75100;Q00535;P49841;Q15078;P24941	0.903772
DB07812	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide	experimental	24963048			P49841;P31751	0.903772
DB07676	3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one	experimental	24894167			Q16566;P49841	0.903772
DB07947	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	experimental	5327109			P17612;P49841;P61925;P31751	0.903772
DB07149	(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one	experimental	16757525			P49841	0.903772
DB07014	2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole	experimental	2079916			P49841	0.903772
DB01356	Lithium	approved	28486	Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.	Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.	P29218;P49841;O14732;P42263	0.903772
DB01772	3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione	experimental	448238			P49841	0.903772
DB07859	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	experimental	11175137			P17612;P49841;P61925;P31751	0.903772
DB00030	Insulin Regular 	approved;experimental		Insulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use. 	Indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. 	P06400;P08069;P98164;P48745;P07339;P16870;P16519;P29120;P06213;Q96C24;P14735;Q16270	0.899577
DB03096	N-Aminoethylmorpholine	experimental	408285			P07339	0.899577
DB07542	5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID	experimental	6323244			P07339	0.899577
DB02216	S-Methylcysteine	experimental	24417			P07339;P16455	0.899577
DB00071	Insulin, porcine	approved		Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure	For the treatment of type I and II diabetes mellitus.	P06400;P08069;P98164;P48745;P07339;P16519;P16870;P01920;P29120;P06213;P01906;Q96C24;P14735;Q16270	0.899577
DB08740	CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE	experimental				P00790;P07339	0.899577
DB03028	1h-Benoximidazole-2-Carboxylic Acid	experimental	233240			P07339	0.899577
DB01065	Melatonin	approved;nutraceutical	896	Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958.  In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature.  Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant.  Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers.	Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. 	P05164;P46597;P16083;P62158;P49286;P27797;P03372;Q92753;P48039;P11678	0.896581
DB04821	Nomifensine	withdrawn	4528	Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.		P21397;P23975;Q01959;P05164;P27338	0.896581
DB00244	Mesalazine	approved	4075	An anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed)	For the treatment of active ulcerative proctitis.	O15111;P09917;P05164;P23219;P35354;P0A5L8;P37231;O14920	0.896581
DB00583	L-Carnitine	approved	10917	Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]	For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.	P43155;O76082;P05164;Q9H015;O43772;P23141;P50416;P23786;Q8N8R3;Q9UKG9;P47989	0.896581
DB00535	Cefdinir	approved	6915944	Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.	For the treatment of the respiratory, skin, soft tissue, and ENT infections caused by <i>H. influenzae</i> (including b-lactamase producing strains), <i>H. parainfluenzae</i> (including b-lactamase producing strains), <i>S. pneumoniae</i> (penicillin-susceptible strains), <i>S. pyogenes</i>, <i>S. aureus</i> (including b-lactamase producing strains), and <i>M. catarrhalis</i>.	P08149;P05164;Q60FT7	0.896581
DB03127	Benzamidine	experimental	444655			P42126;P35030;O00244;P07478;P68400;P00775;Q92876;Q9Y5Y6;P00749;P07477	0.88858509155
DB03046	7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide	experimental	5289529			P00749	0.869845
DB00013	Urokinase	approved		Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator	Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.	P98164;Q03405;P05154;P00747;P00750;P14543;Q9Y5Y6;P00749;P05120;P05121	0.869845
DB07076	6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE	experimental	447734			P00749	0.869845
DB00594	Amiloride	approved	16231	A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)	For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.	P19801;P19634;P78348;Q16515;P37088;P51170;P51172;P51168;P00749	0.869845
DB08072	4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE	experimental	23653530			P00749	0.869845
DB08697	4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide	experimental				P00749	0.869845
DB06855	6-FLUORO-2-(2-HYDROXY-3-ISOBUTOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	experimental	6102526			P00749	0.869845
DB01977	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	experimental	447732			P00749	0.869845
DB02551	6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine	experimental	447731			P00749	0.869845
DB03082	6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide	experimental	448605			P00749	0.869845
DB03782	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	experimental	4286			P00749	0.869845
DB07626	4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide	experimental	23653533			P00749	0.869845
DB03729	2-Amino-5-Hydroxy-Benzimidazole	experimental	162636			P00749	0.869845
DB02473	6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine	experimental	447735			P00749	0.869845
DB02526	CRA_10655	experimental	6119062			P00749;P07477	0.869845
DB02193	2-(2-Hydroxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine	experimental				P00734;P00749;P07477	0.869845
DB03865	6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine	experimental	445843			P00734;P05981;P00749;P07477	0.869845
DB01905	2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine	experimental	5353303			P00749;P07477	0.869845
DB06856	6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE	experimental	445849			P00749	0.869845
DB04172	[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine	experimental	46936909			P00749	0.869845
DB07625	4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide	experimental	23653531			P00749	0.869845
DB03136	4-Iodobenzo[B]Thiophene-2-Carboxamidine	experimental	1746			P00734;P00749;P07477	0.869845
DB03476	Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine	experimental	448841			P00749	0.869845
DB02705	6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine	experimental	447736			P00749	0.869845
DB04059	8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide	experimental	448610			P00749	0.869845
DB03159	CRA_8696	experimental	447476			P00734;P00749;P07477	0.869845
DB06854	2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	experimental	5353305			P00734;P00749	0.869845
DB07122	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	experimental	16758228			P00749	0.869845
DB03876	Thieno[2,3-B]Pyridine-2-Carboxamidine	experimental	5438			P00749;P07477	0.869845
DB07129	(2R)-1-(2,6-dimethylphenoxy)propan-2-amine	experimental	180621			P00749	0.869845
DB02398	6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine	experimental	447733			P00749	0.869845
DB06857	N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE	experimental	4300			P00749	0.869845
DB00691	Moexipril	approved	91270	Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.	For the treatment of hypertension.	Q9BYF1;P12821	0.847083
DB00584	Enalapril	approved		Enalapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to enalaprilat following oral administration. Enalaprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Enalapril may be used to treat essential or renovascular hypertension and symptomatic congestive heart failure. 	For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.	P12821	0.847083
DB01348	Spirapril	approved	5311447	Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.	Spirapril is an ACE inhibitor class drug used to treat hypertension.	P12821	0.847083
DB00178	Ramipril	approved	5362129	Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. 	For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.   	P12821	0.847083
DB01340	Cilazapril	approved		One of the angiotensin-converting enzyme inhibitors (ACE inhibitors) used for hypertension.  It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. [PubChem]	Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.	P12821	0.847083
DB01180	Rescinnamine	approved	5280954	Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from <i>Rauwolfia serpentina</i> and other species of <i>Rauwolfia</i>. [Wikipedia]	For the treatment of hypertension.	P12821	0.847083
DB00722	Lisinopril	approved	5362119	Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. 	For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or &beta;-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. 	Q9BYF1;P12821	0.847083
DB02032	1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid	experimental	688267			P26918;Q9K578;P52700;O08498;Q9KKU4;P12821	0.847083
DB00492	Fosinopril	approved	55891	Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. 	For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. 	P12821	0.847083
DB00881	Quinapril	approved	54892	Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure. 	For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. 	P12821	0.847083
DB00519	Trandolapril	approved	5484727	Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. 	For the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. 	P12821	0.847083
DB00542	Benazepril	approved	5362124	Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.	For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.	P12821	0.847083
DB00790	Perindopril	approved	107807	Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. 	For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. 	P12821	0.847083
DB03740	2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose	experimental	440552	The N-acetyl derivative of glucosamine. [PubChem]		P22303;Q9HYN5;P04062;P12821;P01857;P05884;Q9Y286;P32884;O34928	0.847083
DB01197	Captopril	approved	44093	Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. 	For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, &beta;-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy. 	P14780;P08253;P12821	0.847083
DB00616	Candoxatril	approved		Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), the active enantiomer of candoxatrilat (UK-69578), a potent neutral endopeptidase (NEP) inhibitor used in the treatment of chronic heart failure.	For treatment of hypertension, improve exercise capacity in patients with CHF receiving angiotensin converting enzyme inhibition.	P08473;P12821	0.847083
DB08836	Temocapril	experimental		Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation. 	Temocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction). 	P12821	0.847083
DB01083	Orlistat	approved	3034010	Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.	For obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Also used to reduce the risk for weight regain after prior weight loss. Use of orlistat is pending revision due to reports of liver-related adverse events.	P16233;P49327;P07098	0.445219824209
DB02457	Undecyl-Phosphinic Acid Butyl Ester	experimental	46936391			P07098	0.390938
DB03245	S-4-Nitrobutyryl-Coa	experimental				Q92947	0.231777
DB03147	Flavin-Adenine Dinucleotide	experimental	643975	A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)		P21397;Q9WYT0;P00387;P10902;O06934;Q9KIE5;P20586;P37747;P42593;P77967;P16640;P40859;P18925;P0C278;P61432;Q56839;P05327;Q15067;P08373;P06715;Q51225;P09622;Q52437;P16219;Q9Z4P0;Q9RA47;Q9UKU7;P55792;P00438;P16435;P58558;P24232;P27338;P09063;Q06319;P15559;P38038;P0A9P4;P83223;P28593;Q92947;O95831;Q888A4;P21890;Q9UHQ9;P14920;P00390;Q12882;P37062;Q16881;O31616;P37063;Q47PU3;P12676;P22570;O05783;P35340;P22637;Q7SID9;P06149;P00914;P09788;P47989;Q9RC23;Q94655;P14218;Q72JJ3;Q9AGP8;P55789;Q44532;P16083;P28861;P11310;Q9LAG2;P0AEZ1;Q96RQ9;P07771;P29475;P39662;P19480;P09546;P61497;Q86YB8;O53355;P26440	0.231777
DB08607	(5R)-5-(4-{[(2R)-6-HYDROXY-2,5,7,8-TETRAMETHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL]METHOXY}BENZYL)-1,3-THIAZOLIDINE-2,4-DIONE	experimental	9824580			P10632	0.225504
DB03796	Palmitic Acid	experimental	985	A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids. [PubChem]		Q14541;P00709;O76054;P08100;P10632;O43617;P09466;P50897;P02689;P83812;Q9X1H9	0.225504
DB08326	2-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONE	experimental	6420152			Q96GR2	0.224939
DB03175	1-Proponol	experimental	1031	A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate. [PubChem]		P61626	0.218336
DB04194	Chitotriose	experimental	46936918			P61626	0.218336
DB02772	Sucrose	experimental	46936484	A nonreducing disaccharide composed of glucose and fructose linked via their anomeric carbons. It is obtained commercially from sugarcane, sugar beet (beta vulgaris), and other plants and used extensively as a food and a sweetener. [PubChem]		Q9L5C8;P68133;P0A094;Q9Y3I0;P83689;P11759;P00811;P71119;Q59976;O00244;Q840M4;Q02169;P61626;P05655;Q9L5C7;P22340;Q9ZEU2	0.218336
DB03120	Para-Toluene Sulfonate	experimental	6101			P61626;P09668	0.218336
DB03189	Cu-Cyclam	experimental	656981			P61626	0.218336
DB02250	Cu-Bicyclam	experimental	23644096			P61626	0.218336
DB03487	3-Aminosuccinimide	experimental	32017976			P61626;P0AE67	0.218336
DB06912	UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE	experimental	46937035			P61626	0.218336
DB03013	Di(N-Acetyl-D-Glucosamine)	experimental	46936555			Q54468;P15291;P61626	0.218336
DB03006	4-Aminophenylarsonic Acid	experimental	7389	An arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]		P61626	0.218336
DB00128	L-Aspartic Acid	approved;nutraceutical	5960	One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. [PubChem]	There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.	Q03154;Q5SY84;Q5T6L4;P00966;P22234;P08243;Q546F9;P27708;P07998;P61626;Q9UJS0;O75746;Q96HD9;P30520;Q12797;P14868;Q7L266;P17174;Q6PI48;P45381;Q2TU84;P00505;Q8N142;P43005	0.218336
DB02759	4-Methylumbelliferyl Chitobiose	experimental	46936482			P61626	0.218336
DB04268	Methylumbelliferyl Chitotriose	experimental	46936938			P61626	0.218336
DB03967	Dodecyl Sulfate	experimental	8778			P61626;P37001	0.218336
DB07670	4-METHYL-N-METHYL-N-(2-PHENYL-2H-PYRAZOL-3-YL)BENZENESULFONAMIDE	experimental	447297			P33260	0.215684
DB04233	(Hydroxyethyloxy)Tri(Ethyloxy)Octane	experimental	5414			Q72JD8;Q9K597;P08100;P02931;Q9RBW8;Q9HVJ6;P32722;P04118;P10384;O33407;P16233;Q48152;P05695;Q9HUR5;P76045;P07110;P31243;P06129;A5W4F4;P33247;P0A910;P0A917;P0A915;P39767;P74334	0.213045
DB08222	METHOXYUNDECYLPHOSPHINIC ACID	experimental	446977			P16233;P04118	0.213045
DB00252	Phenytoin	approved	1775	An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. [PubChem]	For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.	Q14524;P35498	0.208914
DB04855	Dronedarone	approved	208898	Dronedarone is a sinus rhythm controller for management of paroxysmal or persistent atrial fibrillation. Classified as a Class III antiarrhythmic but displays properties of all four Vaughan-Williams classes, dronedarone blocks a multitude of channels (sodium, potassium, calcium), and demonstrates antiadrenergic properties. Chemically, it is a benzofuran derivative. FDA approved on July 1, 2009. 	Management of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm. 	P54284;Q08289;P18825;Q12809;O95069;P18089;O00305;P08588;P08913;Q02641;P25100;P35498;P35368;Q13698;O60840;Q01668;P35348;Q13936	0.208914
DB01595	Nitrazepam	approved	4506	A benzodiazepine derivative used as an anticonvulsant and hypnotic.	Used to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.	Q9UN88;P24046;Q16445;P18507;P18505;A8MPY1;O00591;O14764;P48169;P47870;P28476;Q8N1C3;P31644;P14867;P28472;P35498;P47869;P34903;Q99928;P78334	0.208914
DB00909	Zonisamide	approved	5734	Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.	For use as adjunctive treatment of partial seizures in adults with epilepsy.	P21397;P35219;P43166;P27338;O60939;P23280;Q9NY72;Q16790;Q99250;P35218;Q8N1Q1;Q14524;O95180;Q9Y2D0;Q9P0X4;O43497;Q8IWT1;Q9NS85;P35499;P35498;O43570;O75493;Q9NY46;P00918;P22748;P07451;Q07699;Q15858;Q9ULX7;P00915;Q9UI33	0.208914
DB01121	Phenacemide	approved	4753	Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.	Used to control certain seizures in the treatment of epilepsy.	P35498	0.208914
DB04930	Permethrin	approved	40326	A pyrethroid insecticide commonly used in the treatment of lice infestations and scabies. It is a yellow to light orange-brown, low melt-ing solid or viscous liquid.	For the treatment of infestation with <i>Sarcoptes scabiei</i> (scabies).	P35498	0.208914
DB01438	Phenazopyridine	approved	4756	A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. [PubChem]	For the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.	P35498	0.208914
DB00273	Topiramate	approved	5284627	Topiramate (brand name Topamax) is an anticonvulsant drug produced by Ortho-McNeil Neurologics, a division of Johnson & Johnson. It is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays). It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines. [Wikipedia]. A combination product containing phentermine + topiramate extended-release called QSYMIA? is indicated for the management of obesity.	Used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Qsymia? is indicated for the treatment and management of obesity.	P39086;P00918;P14867;P35498;P22748	0.208914
DB03925	ONO-6818	experimental	46936829		Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).	Q9UNI1;P08246	0.199182
DB02114	Para-Isopropylaniline	experimental	7464			Q9UNI1	0.199182
DB03890	N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide	experimental	6323197			Q9UNI1	0.199182
DB03757	(Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine	experimental	46936785			Q9UNI1	0.199182
DB08007	(2R)-3-{[(BENZYLAMINO)CARBONYL]AMINO}-2-HYDROXYPROPANOIC ACID	experimental	24820112			Q9UNI1	0.199182
DB02341	Mdl 101,146	experimental	46936357			Q9UNI1;P08246	0.199182
DB07433	(TERT-BUTYLOXYCARBONYL)-ALANYL-AMINO ETHYL-FORMAMIDE	experimental	5287737			Q9UNI1	0.199182
DB06951	(3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid	experimental	444650			Q9UNI1	0.199182
DB08614	3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)-PYRIDINE ACETAMIDE	experimental	5289460			Q9UNI1	0.199182
DB07956	[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER	experimental	5288602			Q9UNI1	0.199182
DB08641	(2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID	experimental	6323527			Q9UNI1	0.199182
DB03702	2-[4-[[(S)-1-[[(S)-2-[[(Rs)-3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl]Aminocarbonyl]Pyrrolidin-1-Yl-]Carbonyl]-2-Methylpropyl]Aminocarbonyl]Benzoylamino]Acetic Acid	experimental	46936760			Q9UNI1	0.199182
DB07955	(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE	experimental	4634717			Q9UNI1	0.199182
DB01844	Dimethylformamide	experimental	6228			Q9UNI1;P00797	0.199182
DB07957	METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE	experimental	446501			Q9UNI1	0.199182
DB08640	(2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID	experimental	6323526			Q9UNI1	0.199182
DB03202	2-[5-Methanesulfonylamino-2-(4-Aminophenyl)-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-N-(3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl)Acetamide	experimental	5289459			Q9UNI1	0.199182
DB02613	Decylamine-N,N-Dimethyl-N-Oxide	experimental	62452			P54317;P06971;P06653;Q02127	0.194583
DB00805	Minaprine	approved	4199	Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine  is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. 	For the treatment of depression	P21397;P22303;P28223;P11229;P28335;P41595;P21728;P14416;P31645	0.182061
DB04836	Amineptine	illicit;withdrawn	34869	The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.	For the treatment of depression.	P31645;P23975	0.182061
DB01242	Clomipramine	approved	2801	Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette?s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. 	May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette?s disorder).
Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome. 	P28223;P28335;P41595;O67854;P09211;P31645;P23975	0.182061
DB00422	Methylphenidate	approved	4158	A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine. [PubChem]	For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.	P31645;P23975;Q01959	0.182061
DB00176	Fluvoxamine	approved	5324346	Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.	For management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.	P31645	0.182061
DB00579	Mazindol	approved	4020	Tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. [PubChem]	Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m<sup>2</sup>) or in patients with a body mass index of 27 kg/m<sup>2</sup> in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.	P31645;P23975;Q01959	0.182061
DB00852	Pseudoephedrine	approved	7028	An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists. [PubChem]	For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism.	Q01959;P08588;P08913;P07550;P31645;P23975;P35348	0.182061
DB00289	Atomoxetine	approved	54841	Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]	For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.	P31645;P23975	0.182061
DB00321	Amitriptyline	approved	2160	Amitriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amitriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, amitriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amitriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use). 	For the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis. 	P08172;P41145;Q9NZV8;P11229;P08173;P41143;P20309;P28223;P25100;Q09470;P08912;P08913;Q9UK17;Q16620;P08908;P35367;P31645;P04629;P23975;P35348;O43526	0.182061
DB01577	Methamphetamine	illicit;approved	10836	Methamphetamine is a psychostimulant and sympathomimetic drug. It is a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.	For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.	P21397;P27338;P18825;Q96RJ0;Q01959;P18089;Q05940;P08913;P54219;P31645;P23975	0.182061
DB06204	Tapentadol	approved	9838022	Opioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008. 	The immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy. 	P41145;P41143;P35372;P46098;P31645;P23975	0.182061
DB00458	Imipramine	approved	3696	Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. See toxicity section below for a complete listing of side effects. Imipramine may be used to treat depression and nocturnal enuresis in children. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD). 	For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia. 	P08172;P08173;P11229;Q9NZV8;Q9UK17;P28223;P25100;P08912;O67854;P20309;P35367;P31645;P23975;P35348	0.182061
DB01149	Nefazodone	approved;withdrawn	4449	Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia]	For the treatment of depression.	P28223;P28335;Q01959;P08913;P08908;P31645;P23975;P35348;P35368	0.182061
DB00215	Citalopram	approved	2771	Citalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &alpha;- or &beta;-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Citalopram is approved for treatment of depression. Unlabeled indications include mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy. Citalopram has the fewest drug-drug interactions of the SSRIs. 	For the treatment of depression. Unlabeled indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy. 	P35367;P31645;P35348;P11229	0.182061
DB00715	Paroxetine	approved	43815	Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &alpha;- or &beta;-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation. 	Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. 	P08172;P08173;P11229;P28223;P08912;P20309;P31645;P23975	0.182061
DB00540	Nortriptyline	approved	4543	Nortriptyline hydrochloride, the <i>N</i>-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Nortriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use). 	For the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis.	P08172;P08173;P11229;P28223;P25100;P08912;P20309;P08908;P35367;P31645;P23975;P35348	0.182061
DB01363	Ephedra	nutraceutical;approved;withdrawn		Ephedra is an alkaloid chemical compound traditionally obtained from the plant <i>Ephedra sinica</i>. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations.	Ephedra is widely used by athletes, despite a lack of evidence that it enhances athletic performance. Ephedra has also been used for weight loss.	P21397;P27338;P18825;P54219;Q01959;P18089;Q05940;P08588;P08913;P31645;P07550;P23975;P13945	0.182061
DB01114	Chlorpheniramine	approved	2725	A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]	For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.	P35367;P31645;P23975;Q01959	0.182061
DB00656	Trazodone	approved	5533	A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)	For the treatment of depression.	P28223;P28335;P08913;P08908;P35367;P31645;P35348	0.182061
DB00574	Fenfluramine	illicit;withdrawn	3337	Fenfluramine was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis.	For the management of exogenous obesity as a short-term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction.	P31645;P28335;P41595	0.182061
DB01442	MMDA	illicit;experimental	26175	MMDA, or 3-methoxy-4,5-methylenedioxyamphetamine, is a stimulant and psychedelic drug of the amphetamine class. It also acts as an entheogen and an entactogen. MMDA bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg. The effects of MMDA includes feelings of euphoria and warmth, as well as realistic closed-eye visuals.	MMDA is a recreational drug. It has no current medical uses and is a Schedule I controlled substance in the USA at present.	P21397;P27338;P28223;Q01959;Q05940;P54219;P31645;P23975	0.182061
DB04832	Zimelidine	withdrawn	5365247	Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barr? syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. After its ban, it was succeeded by fluvoxamine and fluoxetine (derived from the antihistamine diphenhydramine) in that order, and the other SSRIs.	For the treatment of depression.	P21397;P31645;P27338	0.182061
DB00472	Fluoxetine	approved	3386	Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &alpha;- or &beta;-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Flouxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.	Labeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon. 	P31645	0.182061
DB06700	Desvenlafaxine	approved	125017	Desvenlafaxine, the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. 	Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.	P31645;P23975	0.182061
DB00193	Tramadol	approved	33741	A narcotic analgesic proposed for moderate to severe pain. It may be habituating. [PubChem]
	Indicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.	P41145;P41143;P28335;Q8TCU5;P35372;P20309;Q693P7;P31645;P23975	0.182061
DB00344	Protriptyline	approved	4976	Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression. 	For the treatment of depression. 	P31645;P23975	0.182061
DB01472	4-Methoxyamphetamine	illicit;experimental	31721			P21397;P27338;Q01959;Q05940;P08913;P31645;P35348	0.182061
DB04896	Milnacipran	approved	65833	Milnacipran is an antidepressant of the serotonin-norepinephrine reuptake inhibitor class. It more potently inhibits norepinephrine uptake than serotonin. It is provided as a racemic mixture. FDA approved in January 2009. 	Milnacipran is used to treat moderate to severe clinical depression but this indication is not yet FDA-approved in the USA. Milnacipran is labelled for the treatment of fibromyalgia pain. 	P31645;P23975;Q05586	0.182061
DB00285	Venlafaxine	approved	5656	Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006. [Wikipedia]	For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.	P31645;P23975;Q01959	0.182061
DB01142	Doxepin	approved		Doxepin hydrochloride is a dibenzoxepin-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, doxepin does not affect mood or arousal, but may cause sedation. In depressed individuals, doxepin exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as doxepin and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Doxepin has less sedative and anticholinergic effects than amitriptyline. See toxicity section below for a complete listing of side effects. Doxepin may be used to treat depression and insomnia. Unlabeled indications include chronic and neuropathic pain, and anxiety. Doxepin may also be used as a second line agent to treat idiopathic urticaria. 	Labeled indications: depression and insomnia. Unlabeled indications: chronic and neuropathic pain, anxiety, idiopathic urticaria.	P08172;P08173;P28335;P11229;P18825;P14416;P28223;P25021;P41595;P18089;P08912;P08913;P25100;P20309;P35368;P35367;P31645;P23975;P35348;P08908	0.182061
DB06701	Dexmethylphenidate	approved	4158	Dexmethylphenidate is the dextrorotary form of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD). 	Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment.	P31645;P23975;Q01959	0.182061
DB01175	Escitalopram	approved	146570	Escitalopram, the <i>S</i>-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &alpha;- or &beta;-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). 	Labeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients. 	P11229;Q01959;P35367;P31645;P23975;P35348	0.182061
DB01191	Dexfenfluramine	illicit;approved;withdrawn		Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.	For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet	P31645;P28335	0.182061
DB00661	Verapamil	approved	2520	A calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]	For the treatment of hypertension, angina, and cluster headache prophylaxis.	P54284;Q14524;Q00975;Q12809;O00555;Q14654;Q08289;Q9P0X4;Q13936;Q02641;O00305;O43497;P31645;Q13698;O60840;Q01668	0.182061
DB01105	Sibutramine	illicit;approved;withdrawn	5210	Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines. Sibutramine is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.	For the treatment of obesity.	P31645;P23975;Q01959	0.182061
DB01454	3,4-Methylenedioxymethamphetamine	illicit;experimental	1615	An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. [PubChem] 	Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.	P28223;P28335;Q01959;P41595;Q05940;P31645;P23975	0.182061
DB01151	Desipramine	approved	2995	Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use). 	For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management. 	P08172;P08173;P28223;P11229;P17405;O67854;P08912;P08588;P20309;P07550;P35367;P31645;P23975;P35348	0.182061
DB00191	Phentermine	illicit;approved	4771	A central nervous system stimulant and sympathomimetic with actions and uses similar to those of dextroamphetamine. It has been used most frequently in the treatment of obesity. [PubChem]. Some common brand names for phentermine are Adipex-P? and Suprenza?. Phentermine is also available in combination medications such as Qsymia?.	For the treatment and management of obesity.	P21397;P31645;P23975;Q01959;P27338	0.182061
DB00907	Cocaine	illicit;approved		An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. [PubChem]	For the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.	Q9Y5Y9;P08172;Q14524;P11229;Q01959;Q9UI33;P31645;P23975	0.182061
DB00514	Dextromethorphan	approved		The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity. [PubChem]	For treatment and relief of dry cough.	Q8TCU5;P31645;Q99720;Q5T1J1;Q15822	0.182061
DB00543	Amoxapine	approved	2170	Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation. 	For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.	P11229;P14867;P21728;P08913;P14416;P31645;P23975;P35348	0.182061
DB00476	Duloxetine	approved	60835	Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.

Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia.

Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.	For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.	P31645;P23975;Q01959	0.182061
DB00726	Trimipramine	approved	5584	Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]	For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance	P28223;Q01959;P18089;P21728;P14416;P08908;P35367;P31645;P23975;P35348;P35368	0.182061
DB06148	Mianserin	approved	4184	A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favor of Mirtazapine.	For the treatment of depression.	P28335;P28223;P08913;P35367;P31645;P23975	0.182061
DB01104	Sertraline	approved	68617	Sertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize &alpha;- or &beta;-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Sertraline may be used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (social phobia). 	For the management of major depressive disorder, posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder with or without agoraphobia, premenstrual dysphoric disorder, social phobia, premature ejaculation, and vascular headaches.	P31645;Q01959	0.182061
DB04178	Di-Stearoyl-3-Sn-Phosphatidylcholine	experimental	5313335			P12235;P17213	0.181145
DB00157	NADH	approved;nutraceutical	439153	NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). It forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage.(Dorland, 27th ed)	Some evidence suggests that NADH might be useful in treating Parkinson's disease, chronic fatigue syndrome, Alzheimer's disease and cardiovascular disease.	P09601;P40939;P07864;Q16878;P03891;P00374;O14561;P13995;P40394;Q00796;P51553;P56937;Q9UDR5;P00390;P00326;P20839;P40925;P49821;P40926;O43920;P30043;Q9UBM7;Q02338;Q08426;O95479;P48728;P00367;O14556;Q13630;P31937;Q6ZMR3;P30519;P03897;P00387;O00483;P53004;P29803;P52895;Q9Y6M9;P47895;P15121;Q16795;O96000;P08559;Q16798;P16219;P08319;P30838;P03886;P26439;P43353;P49189;P30837;P19404;Q16718;Q02252;P03905;P80365;P03901;P03923;O75438;P51970;P42330;Q92781;Q99714;O95139;P07327;Q04828;P28845;P05093;P05091;O43181;O43674;P21695;O43837;P56556;P03915;P12268;O43175;O75380;Q9NRX3;Q16836;O75306;Q15738;P04035;P17568;P48448;O00217;P49448;O95182;P04406;P10515;P17516;P00338;P09417;O43677;P11177;O43678;O15239;O75251;Q86Y39;O43676;P11766;Q15800;P50213;P00325;P48163;P32322;P15428;Q96C36;O95298;O95299;Q9P0J0;P07195;P14679;Q9BYZ2;Q13423;P51648;P51649;O60701;P56181;P30038;O75489;P09622;P00352;O94788;O95168;O95169;P23368;O95167;Q02928;P11586;P51659;Q02218;Q92506;P28331;O95178;P16083;Q9UI09;P14061;P14060;P49419;P37059;P37058	0.174546